Kenneth Brian Gordon, MD

Chair, Professor

Request an Appointment

Location

Dermatology - Froedtert Cancer Center
9200 West Wisconsin Avenue
Milwaukee, WI 53226

Specialties

Dermatology

New & Established Patients Call

(414) 805-3666

Overview

Diseases and Conditions

Inflammatory Skin Disorders
Psoriasis
Psoriatic Arthritis

Patients Ages Seen

Adult
Senior

Languages

English

Hospital Affiliations

Froedtert Hospital – Milwaukee
Zablocki VA Medical Center – Milwaukee

Board Certifications

Dermatology

Clinic Locations

Dermatology - Froedtert Cancer Center

9200 West Wisconsin Avenue
Milwaukee, WI 53226
(414) 805-5320
Get Directions

Biography

Education and Training

Doctor of Medicine - Columbia University College of Physicians and Surgeons - New York, NY (1990)
Residency in Internal Medicine - Beth Israel Hospital - Boston, MA (1990-1993)
Residency in Dermatology - Northwestern University Medical School - Chicago, IL (1993-1997)
Fellowship in Immunology - Northwestern University Medical School - Chicago, IL (1995-1997)

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

(Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.) J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949.
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

(Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L.) Br J Dermatol. 2018 10;179(4):984-986.
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.

(Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G.) J Am Acad Dermatol. 2018 Aug;79(2):294-301.e6.
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.

(Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD.) J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1297-1304.
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.

(Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.) J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1305-1313.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

(Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.) Br J Dermatol. 2018 08;179(2):320-328.
Common and Not-So-Common Comorbidities of Psoriasis.

(Menter MA, Armstrong AW, Gordon KB, Wu JJ.) Semin Cutan Med Surg. 2018 Feb;37(2S):S48-S51.
Practical Strategies for Optimizing Management of Psoriasis.

(Wu JJ, Armstrong AW, Gordon KB, Menter MA.) Semin Cutan Med Surg. 2018 Feb;37(2S):S52-S55.
The Evolving Landscape of Psoriasis Treatment.

(Armstrong AW, Gordon KB, Menter MA, Wu JJ.) Semin Cutan Med Surg. 2018 Feb;37(2S):S39-S43.
Treating to Target-A Realistic Goal in Psoriasis?

(Gordon KB, Armstrong AW, Menter MA, Wu JJ.) Semin Cutan Med Surg. 2018 Feb;37(2S):S44-S47.
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.

(Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM.) J Am Acad Dermatol. 2017 Dec;77(6):1030-1037.
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.

(Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B.) Value Health. 2017 09;20(8):1174-1179.